Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults

OBJECTIVE: We evaluated safety, antiviral, immunomodulatory and anti-inflammatory properties of aprepitant – a neurokinin 1 receptor antagonist. DESIGN: Phase IB randomized, placebo-controlled, double-blinded study. METHODS: Eighteen patients were randomized (nine to aprepitant and nine to placebo)....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:AIDS
Egile Nagusiak: Tebas, Pablo, Spitsin, Sergei, Barrett, Jeffrey S., Tuluc, Florin, Elci, Okan, Korelitz, James J., Wagner, Wayne, Winters, Angela, Kim, Deborah, Catalano, Renae, Evans, Dwight L., Douglas, Steven D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lippincott Williams & Wilkins 2015
Gaiak:
Clinical Science
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4472318/
https://ncbi.nlm.nih.gov/pubmed/25915168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAD.0000000000000638
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak